Metabolic State Medicine

What if metabolic state is the variable that matters?

Across neurodegeneration, oncology, and epilepsy—the underlying driver is metabolic. We're building the first platform to control it.

See the Evidence Partner With Us

The pattern is metabolic.
The opportunity is enormous.

In Alzheimer's disease, FDG-PET shows glucose hypometabolism decades before symptoms appear. The brain is energy-starved long before plaques accumulate.

In immuno-oncology, 75–85% of patients don't respond to checkpoint inhibitors. The reason: T-cells exhaust in the metabolically hostile tumor microenvironment—they can't fuel themselves when tumor cells monopolize glucose.

In drug-resistant epilepsy, 30% of patients fail all medications. Yet metabolic intervention—the ketogenic diet—achieves 50–90% seizure reduction.

These are not three diseases. They are three manifestations of the same problem.

85%
IO patients who don't respond to checkpoint inhibitors
Nature Reviews Cancer, 2021
6.7M
Americans with Alzheimer's—all with hypometabolic brains
Alzheimer's Association, 2024
50–90%
Seizure reduction when metabolic state is controlled
Kossoff et al., Lancet Neurology

What if the drugs aren't failing? What if they're being deployed into the wrong metabolic state?

Controlling the state that determines whether therapy works.

Not treating symptoms. Not chasing targets. Controlling the physiological state that determines therapeutic response. This is the lever that's been missing.

Four programs. One platform.

SNV-401
Ketogenic Diet in a Pill
Angelman, Dravet, GLUT1-DS
First pharmaceutical capture of 100 years of KD efficacy. 505(b)(2) + Orphan + PRV eligible.
IND-Enabling
SNV-601
IO Metabolic Rescue
ICB-Refractory NSCLC
T-cell fuel in the TME. Tumors can't use ketones—T-cells can. Designed for the 85% who don't respond.
IND-Enabling
SNV-201
Bioenergetic Rescue for AD
Early Alzheimer's Disease
3× ATP restoration. 60% Aβ clearance in 24h (preclinical). Addresses what anti-amyloid cannot.
Preclinical
SNV-301
Metabolic Psychiatry
Treatment-Resistant Schizophrenia
Restoring E/I balance via metabolic intervention. Addressing bioenergetic dysfunction in psychosis.
Research

Interested in partnering?

Email

Brent@Senoviabiosciences.com

Phone

256-766-3824